GLP-1 Weight Loss Results by Starting BMI

    By Trimi Medical Team10 min read

    Your starting BMI is one of the most important factors in predicting total weight loss on GLP-1 medications. Generally, patients with higher starting BMI lose more total weight (in pounds), while percentage body weight lost is more consistent across BMI categories. Here is what the clinical data shows for each BMI range.

    Medical Disclaimer: This article is for informational purposes only. These are population averages; individual results vary significantly based on many factors beyond starting BMI.

    Semaglutide Results by Starting BMI (12-Month Data)

    Starting BMIStarting Weight (approx.)Avg. % LostAvg. lbs LostExpected End Weight
    27-30175-195 lbs12-15%21-29 lbs154-166 lbs
    30-35195-230 lbs13-16%25-37 lbs170-193 lbs
    35-40230-265 lbs14-17%32-45 lbs198-220 lbs
    40+265+ lbs13-16%34-50+ lbs215-240+ lbs

    Tirzepatide Results by Starting BMI (12-Month Data)

    Starting BMIStarting Weight (approx.)Avg. % Lost (15 mg)Avg. lbs Lost
    27-30175-195 lbs17-20%30-39 lbs
    30-35195-230 lbs18-22%35-51 lbs
    35-40230-265 lbs19-23%44-61 lbs
    40+265+ lbs18-22%48-65+ lbs

    Key Findings Across BMI Categories

    • Percentage lost is remarkably consistent: Whether your starting BMI is 28 or 42, GLP-1 medications produce roughly 13-17% weight loss (semaglutide) or 17-23% (tirzepatide). The biological response is proportional.
    • Absolute pounds differ significantly: A 15% loss translates to 26 lbs at 175 lbs but 40 lbs at 265 lbs. Patients with higher starting weights see larger absolute numbers.
    • BMI 30-40 is the sweet spot: Some data suggests slightly higher percentage losses in the BMI 30-40 range compared to very high BMI (40+), possibly because extreme obesity involves additional metabolic barriers.
    • Lower BMI patients still benefit significantly: Patients with BMI 27-30 who qualify based on comorbidities achieve meaningful weight loss and health improvements.

    Factors Beyond BMI That Predict Results

    • Early response: Patients who lose 4%+ in the first 12 weeks tend to achieve the best long-term results.
    • Medication adherence: Consistent weekly dosing produces significantly better results than missed doses.
    • Diet quality: High-protein diets preserve muscle and enhance fat loss.
    • Physical activity: Exercise, especially resistance training, improves body composition beyond scale weight.
    • Sleep quality: Poor sleep impairs weight loss across all BMI categories.
    • Genetics: Emerging research identifies genetic variants that predict GLP-1 response.

    Frequently Asked Questions

    Do people with higher BMI lose more weight on GLP-1 medications?

    More total pounds, yes. But the percentage of body weight lost is similar across BMI categories. Someone at BMI 40+ may lose 40-60 lbs while someone at BMI 28 may lose 20-30 lbs, but both are achieving approximately 15% of their starting weight.

    Can you take GLP-1 medications with a BMI under 30?

    Yes, if your BMI is 27-29.9 and you have at least one weight-related comorbidity. Some compounded GLP-1 programs may have slightly different criteria.

    Does BMI predict how well GLP-1 medications will work?

    Starting BMI is one predictor but not the strongest. Diet, exercise, adherence, genetics, and individual biology all play significant roles regardless of starting BMI.

    Find out what results you can expect. Start with a free eligibility check at Trimi.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading